Clinical Trial Update: A Study With Imlifidase in Anti-GBM Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of imlifidase for anti-glomerular basement membrane disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-glomerular Basement Membrane Disease
• Goodpasture Syndrome

Drugs mentioned

• Imlifidase (imlifidase)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease | Phase 3 | Status: TERMINATED